Abstract:
The advent of COVID-19 has given the tasks to healthcare professionals of quickly diagnosing and
providing medical care to patients. Currently, an intensive study of the clinical and epidemiological characteristics of the disease is being carried out, and the new ways of its prevention and treatment are
being developed. The most common clinical manifestation of a new variant of coronavirus infection
is bilateral pneumonia (viral diffuse alveolar damage with microangiopathy); the development of acute
respiratory distress syndrome (ARDS) was recorded in 3-4% of patients. Hypercoagulable syndrome
with thrombosis and thromboembolism are developing in some organs of patients, other organs and
systems are also affected (central nervous system, myocardium, kidneys, liver, gastrointestinal tract,
endocrine and immune systems); the development of sepsis and septic shock is possible [1]. The use
of anticoagulant therapy with low molecular weight heparins (LMWH) reduces mortality in
hospitalized patients with severe form of COVID-19, likely due to its anti-inflammatory and antiviral
properties [5]. There is no proven benefit of one LMWH over another. In the suspicion of the
development of venous thromboembolic complications, anticoagulant therapy can be started in
therapeutic doses before the diagnosis is confirmed: during the period of inpatient treatment, LMWH
should be preferred, especially Enoxaparin sodium (Clexane) or UFH, and after discharge from the
hospital, it is recommended to switch to direct parenteral anticoagulants, in particular Rivaroksaban
NOBEL for a period of at least 3 months [1].
The purpose of this work is to carry out a comparative assessment of the effect of anticoagulants on
the clinical and laboratory course and the outcome of coronavirus infection (COVID-19).
